Elaine Gray

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6206157/publications.pdf

Version: 2024-02-01

687363 752698 1,008 25 13 20 h-index citations g-index papers 25 25 25 1632 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Pharmacology of Heparin and Related Drugs. Pharmacological Reviews, 2016, 68, 76-141.	16.0	250
2	Animal models of mechanisms of <scp>SARSâ€CoVâ€2</scp> infection and <scp>COVIDâ€19</scp> pathology. British Journal of Pharmacology, 2020, 177, 4851-4865.	5.4	158
3	The Anticoagulant and Antithrombotic Mechanisms of Heparin. Handbook of Experimental Pharmacology, 2012, , 43-61.	1.8	111
4	The US regulatory and pharmacopeia response to the global heparin contamination crisis. Nature Biotechnology, 2016, 34, 625-630.	17.5	93
5	Characterization of Unfractionated Heparin: Comparison of Materials from the last 50 Years. Thrombosis and Haemostasis, 2000, 84, 1052-1056.	3.4	72
6	Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. Thrombosis and Haemostasis, 2014, 112, 932-940.	3.4	54
7	Protamine neutralisation of low molecular weight heparins and their oligosaccharide components. Analytical and Bioanalytical Chemistry, 2011, 399, 763-771.	3.7	52
8	Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia, 2020, 26, 151-155.	2.1	44
9	Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood. PLoS ONE, 2020, 15, e0233644.	2.5	37
10	Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. British Journal of Haematology, 2020, 191, 347-362.	2.5	32
11	Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia, 2020, 26, 6-16.	2.1	31
12	International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Journal of Thrombosis and Haemostasis, 2021, 19, 3177-3192.	3.8	20
13	Precipitation and Neutralization of Heparin from Different Sources by Protamine Sulfate. Pharmaceuticals, 2017, 10, 59.	3.8	19
14	Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia, 2022, 28, 515-519.	2.1	7
15	Potency estimates for recombinant factor IX in the one-stage clotting assay are influenced by more than just the choice of activated partial thromboplastin time reagent. Haemophilia, 2018, 24, e363-e368.	2.1	6
16	Activity measurements of dalcinonacog alfa. Haemophilia, 2020, 26, 346-353.	2.1	6
17	Biochemical and functional characterization of glycosaminoglycans released from degranulating rat peritoneal mast cells: Insights into the physiological role of endogenous heparin. Pulmonary Pharmacology and Therapeutics, 2016, 41, 96-102.	2.6	5
18	Multiplex genome editing of mammalian cells for producing recombinant heparin. Metabolic Engineering, 2022, 70, 155-165.	7.0	5

#	Article	IF	CITATIONS
19	Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products. Biologicals, 2020, 67, 88-93.	1.4	3
20	The traceability of commercial plasma calibrators to the plasma International Standards for factor VIII and factor IX. International Journal of Laboratory Hematology, 2020, 42, 810-818.	1.3	3
21	Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products. Vox Sanguinis, 2020, 116, 656-664.	1.5	O
22	Title is missing!. , 2020, 15, e0233644.		0
23	Title is missing!. , 2020, 15, e0233644.		O
24	Title is missing!. , 2020, 15, e0233644.		0
25	Title is missing!. , 2020, 15, e0233644.		0